A RANDOMIZED CONTROLLED TRIAL OF LOW DOSE ANTI-THYMOCYTE GLOBULIN PLUS RITUXIMAB VERSUS CONVENTIONAL DOSE OF ANTI -THYMOCYTE GLOBULIN ALONE AS INDUCTION AGENT IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS. - Current Issue

A RANDOMIZED CONTROLLED TRIAL OF LOW DOSE ANTI-THYMOCYTE GLOBULIN PLUS RITUXIMAB VERSUS CONVENTIONAL DOSE OF ANTI -THYMOCYTE GLOBULIN ALONE AS INDUCTION AGENT IN HIGH-RISK RENAL TRANSPLANT RECIPIENTS. - Current Issue - IJAR